In this article:

Robert W. Baird Thinks VistaGen Therapeutics’ Stock is Going to Recover

In this article:
In this article:

In a report issued on February 10, Brian Skorney from Robert W. Baird maintained a Buy rating on VistaGen Therapeutics (VTGNResearch Report), with a price target of $9.00. The company’s shares closed last Friday at $1.50, close to its 52-week low of $1.40.

According to TipRanks.com, Skorney is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -5.1% and a 43.6% success rate. Skorney covers the Healthcare sector, focusing on stocks such as Eiger Biopharmaceuticals, Vertex Pharmaceuticals, and Enanta Pharmaceuticals.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for VistaGen Therapeutics with a $9.00 average price target, which is a 448.8% upside from current levels. In a report issued on February 11, William Blair also reiterated a Buy rating on the stock.

See today’s best-performing stocks on TipRanks >>

Based on VistaGen Therapeutics’ latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $358K and GAAP net loss of $12.79 million. In comparison, last year the company earned revenue of $334K and had a GAAP net loss of $3.3 million.

Based on the recent corporate insider activity of 17 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of VTGN in relation to earlier this year. Last month, Jerrold Duane Dotson, the VP, CFO AND SECRETARY of VTGN bought 34,375 shares for a total of $34,375.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

VistaGen Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of new generation medicines to treat diseases and disorders of the central nervous system. Its portfolio focuses on three clinical-stage product; neuropathic pain (NP), levodopa-induced dyskinesia (LID), social anxiety disorder (SAD) and suicidal ideation (SI). Its product include AV-101 product and PH10 neuroactive nasal spray.The company was founded by H. Ralph Snodgrass and Gordon Keller on May 26, 1998 and is headquartered in South San Francisco, CA.

Read More on VTGN:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More

Latest News Feed

In this article:

Latest News Feed